Clinical Trials Browser

patritumab × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01211483 2021-06-16

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Phase 1/2 Completed

222 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02633800 2019-01-07

Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Phase 2 Terminated

87 enrolled 13 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms by Site

NCT02350712 2018-09-11

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT02134015 2018-01-23

HER3-Lung

Phase 3 Terminated

145 enrolled 20 charts

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT01512199 2017-10-18

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT01479023 2013-12-20

Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors

Phase 1 Terminated

LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

NCT00730470 2010-07-29

Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors

Phase 1 Completed

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2